Keup Corinna, Kimmig Rainer, Kasimir-Bauer Sabine
Department of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45122 Essen, Germany.
Diagnostics (Basel). 2022 Mar 31;12(4):870. doi: 10.3390/diagnostics12040870.
Liquid biopsy is a promising technique for clinical management of oncological patients. The diversity of analytes circulating in the blood useable for liquid biopsy testing is enormous. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and extracellular vesicles (EVs), as well as blood cells and other soluble components in the plasma, were shown as liquid biopsy analytes. A few studies directly comparing two liquid biopsy analytes showed a benefit of one analyte over the other, while most authors concluded the benefit of the additional analyte. Only three years ago, the first studies to examine the value of a characterization of more than two liquid biopsy analytes from the same sample were conducted. We attempt to reflect on the recent development of multimodal liquid biopsy testing in this review. Although the analytes and clinical purposes of the published multimodal studies differed significantly, the additive value of the analytes was concluded in almost all projects. Thus, the blood components, as liquid biopsy reservoirs, are complementary rather than competitive, and orthogonal data sets were even shown to harbor synergistic effects. The unmistakable potential of multimodal liquid biopsy testing, however, is dampened by its clinical utility, which is yet to be proven, the lack of methodical standardization and insufficiently mature reimbursement, logistics and data handling.
液体活检是一种用于肿瘤患者临床管理的很有前景的技术。可用于液体活检检测的血液中循环分析物种类繁多。循环肿瘤细胞（CTC）、游离DNA（cfDNA）和细胞外囊泡（EV），以及血浆中的血细胞和其他可溶性成分，都被视为液体活检分析物。一些直接比较两种液体活检分析物的研究表明一种分析物优于另一种，而大多数作者则得出了额外分析物的益处。就在三年前，才开展了首批研究，以检验对同一样本中两种以上液体活检分析物进行表征的价值。在本综述中，我们试图对多模态液体活检检测的最新进展进行思考。尽管已发表的多模态研究的分析物和临床目的差异很大，但几乎所有项目都得出了分析物的附加值。因此，作为液体活检储备库的血液成分是互补而非竞争的，甚至已证明正交数据集具有协同效应。然而，多模态液体活检检测的巨大潜力因以下因素而受到抑制：其临床效用尚待证明、缺乏方法标准化以及报销、物流和数据处理不够成熟。
